Cargando…

Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection

This study aimed to assess the prevalence of natural resistance-associated substitutions (RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV)-infected patients from Buenos Aires, Argentina, and to determine their effect on therapy outcome. Additionally, virological, clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esposito, Isabella, Marciano, Sebastián, Haddad, Leila, Galdame, Omar, Franco, Alejandra, Gadano, Adrián, Flichman, Diego, Trinks, Julieta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356817/ https://www.ncbi.nlm.nih.gov/pubmed/30577623 http://dx.doi.org/10.3390/v11010003

Ejemplares similares

Hepatitis B Virus Genotype Distribution and Genotype-Specific BCP/preCore Substitutions in Acute and Chronic Infections in Argentina
por: González López Ledesma, María Mora, et al.
Publicado: (2015)

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
por: Trinks, Julieta, et al.
Publicado: (2017)

Hepatitis C in Argentina: epidemiology and treatment
por: Gaite, Luis Alejandro, et al.
Publicado: (2014)

Clinical utility of pharmacogenomics in the management of hepatitis C
por: Trinks, Julieta, et al.
Publicado: (2014)

Unexpected high seroprevalence of hepatitis E virus in patients with alcohol-related cirrhosis
por: Fantilli, Anabella C., et al.
Publicado: (2019)

Analysis of the Molecular Evolution of Hepatitis B Virus Genotypes in Symptomatic Acute Infections in Argentina
por: Rodrigo, María Belén, et al.
Publicado: (2016)

Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations
por: Pontoriero, Ana Cecilia, et al.
Publicado: (2015)

Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies
por: Marciano, Sebastián, et al.
Publicado: (2019)

Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure
por: Rodrigues, João Paulo Vilela, et al.
Publicado: (2022)

The Role of Serum Biomarkers in Predicting Fibrosis Progression in Pediatric and Adult Hepatitis C Virus Chronic Infection
por: Valva, Pamela, et al.
Publicado: (2011)

Serum Apoptosis Markers Related to Liver Damage in Chronic Hepatitis C: sFas as a Marker of Advanced Fibrosis in Children and Adults While M30 of Severe Steatosis Only in Children
por: Valva, Pamela, et al.
Publicado: (2013)

The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures
por: Popping, Stephanie, et al.
Publicado: (2021)

Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
por: Ridruejo, Ezequiel, et al.
Publicado: (2021)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
por: Chen, Zhi-wei, et al.
Publicado: (2017)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C
por: Itakura, Jun, et al.
Publicado: (2020)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
por: Mushtaq, Saima, et al.
Publicado: (2022)

Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China
por: Li, Zhao, et al.
Publicado: (2017)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

Biological Characterization of Hepatitis B virus Genotypes: Their Role in Viral Replication and Antigen Expression
por: Elizalde, María Mercedes, et al.
Publicado: (2021)

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
por: Poordad, Fred, et al.
Publicado: (2017)

Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients
por: Marascio, Nadia, et al.
Publicado: (2016)

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
por: Poordad, Fred, et al.
Publicado: (2018)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization
por: Pham, Long V., et al.
Publicado: (2022)

Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey
por: Sahin, Ahmet, et al.
Publicado: (2023)

Natural killer cells act as rheostats modulating antiviral T cells
por: Waggoner, Stephen N., et al.
Publicado: (2011)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies
por: Grebely, Jason, et al.
Publicado: (2018)

Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
por: Tavares, Rita Chelly Felix, et al.
Publicado: (2018)

Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens
por: Akiyama, Matthew J, et al.
Publicado: (2021)

Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
por: Kim, Kyung-Ah, et al.
Publicado: (2023)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen, Mohammed, et al.
Publicado: (2017)

Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
por: Toyoda, Hidenori
Publicado: (2019)

Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_39s73lfdr5lnjh2k863sals4hg